Clinical MedicineUpdated Aug 20, 2026Version v1
Reviewed milestones, validation shifts, standards, datasets, and debates linked to public evidence.
Evidence from New England Journal of Medicine indicates that Liraglutide group lost a mean of 8.4 kg vs. 2.8 kg in placebo group (difference -5.6 kg). This is tracked as a clinical because it changes how GLP-1 receptor agonists for obesity treatment is understood, validated, or applied.
Evidence from New England Journal of Medicine indicates that Oral semaglutide demonstrated non-inferiority to placebo in reducing major adverse cardiovascular events in patients with type 2 diabetes at high cardiovascular risk. This is tracked as a clinical because it changes how GLP-1 receptor agonists for obesity treatment is understood, validated, or applied.
Evidence from Circulation indicates that GLP-1 RAs have multiple beneficial effects beyond glycemic control, including weight reduction and cardiovascular risk factor improvement. This is tracked as a standard because it changes how GLP-1 receptor agonists for obesity treatment is understood, validated, or applied.
Evidence from Molecular Metabolism indicates that LY3298176 activates both GIP and GLP-1 receptors in vitro. This is tracked as a clinical because it changes how GLP-1 receptor agonists for obesity treatment is understood, validated, or applied.
Evidence from Frontiers in Endocrinology indicates that Rational design led to liraglutide and semaglutide with extended half-lives and therapeutic efficacy. This is tracked as a clinical because it changes how GLP-1 receptor agonists for obesity treatment is understood, validated, or applied.
Evidence from New England Journal of Medicine indicates that 40-59% NASH resolution with semaglutide vs. 17% with placebo. This is tracked as a clinical because it changes how GLP-1 receptor agonists for obesity treatment is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from Frontiers in Endocrinology indicates that GLP-1RAs possess significant extrapancreatic effects. This is tracked as a clinical because it changes how GLP-1 receptor agonists for obesity treatment is understood, validated, or applied. It is supported by 3 papers in the same timeline signal.
Evidence from Expert Opinion on Drug Safety indicates that Disproportionate reporting of suicidal ideation and 'depression/suicidal' for semaglutide and liraglutide. This is tracked as a method because it changes how GLP-1 receptor agonists for obesity treatment is understood, validated, or applied.
Evidence from New England Journal of Medicine indicates that Orforglipron at 36 mg resulted in an 11.2% mean weight reduction compared to 2.1% with placebo. This is tracked as a clinical because it changes how GLP-1 receptor agonists for obesity treatment is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from Molecular Metabolism indicates that GLP-1 RAs have evolved from short-acting to long-acting and oral formulations with improved efficacy. This is tracked as a standard because it changes how GLP-1 receptor agonists for obesity treatment is understood, validated, or applied.
Evidence from New England Journal of Medicine indicates that A primary cardiovascular event occurred in 6.5% of the semaglutide group vs. 8.0% of the placebo group (HR 0.80, P<0.001). This is tracked as a clinical because it changes how GLP-1 receptor agonists for obesity treatment is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.